Cardin DB, et al. - In patients with refractory metastatic pancreatic cancer (rMPC), researchers tested the effectiveness of ganetespib via analyzing data of patients with rMPC who received 175 mg/m² ganetespib intravenously once weekly for 3 weeks in 4-week cycles. Diarrhea, abdominal pain, fatigue, nausea, vomiting, and hyponatremia were grade 3 treatment-related toxicities. The results obtained from this phase II study indicate that single-agent ganetespib was tolerable with only modest disease control in rMPC. They found that rMPC to be resistant to chemotherapy, and given the emerging data in lung and rectal cancers and additionally in pancreatic cancer cell lines, implied improved activity of ganetespib if used in combination with cytotoxic agents.